WilmerHale Represents Trevi Therapeutics in Securing $50M in Series C Financing
Trevi Therapeutics, Inc. announced that they have completed a Series C financing of $50.5 million led by New Enterprise Associates. The company plans to use the proceeds from the financing to advance the development of Nalbuphine® ER, a drug with a dual agonist/antagonist mechanism of action uniquely suited to treating itch associated in various dermatologic, metabolic, hematologic, and neuropathic conditions.
The WilmerHale deal team counseling Trevi Therapeutics was led by Stuart Falber and included Sam Rothberg and Cara Fonseca.
Read Trevi Therapeutics' press release for more information.